FDA and European Medicines Agency accept marketing application submissions for bimekizumab for treatment of adults with moderate to severe plaque psoriasis

Submission for this humanised monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, is supported by 3 phase III studies (BE VIVID, BE READY and BE SURE), which showed superiority vs. placebo, ustekinumab and adalimumab in achieving skin clearance at week 16.

Source:

Biospace Inc.